Phoenix rising: Gene therapy makes a comeback

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 8, 2012, Pages 632-640

  Limberis, Maria P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

gene therapy; genetic disease; genetic vectors

Indexed keywords

ADENOSINE DEAMINASE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL; CYTOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; METABOLISM; METHODOLOGY; RETROVIRUS; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ADENOSINE DEAMINASE; ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84864448098     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms036     Document Type: Review

References (124)

1. Watson JD and Crick FH. The structure of DNA. Cold Spring Harb Symp Quant Biol 1953, 18: 123-131.
2. Keeler CE. Gene therapy. J Hered 1947, 38: 294-298.
3. Friedmann T and Roblin R. Gene therapy for human genetic disease? Science 1972, 175: 949-955.
4. Blaese RM, Culver KW, Chang L, Anderson WF, Mullen C, Nienhuis A and Carter C, et al. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Hum Gene Ther 1993, 4: 521-527. (Pubitemid 24308320)
5. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M and Shearer G, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270: 475-480.
6. Wiehe M and Arndt K. Cystic fibrosis: a systems review. AANA J 2010, 78: 246-251.
7. Drumm ML, Pope HA, Cliff WH, Rommens JM, Marvin SA, Tsui LC and Collins FS, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990, 62: 1227-1233.
8. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z and Zielenski J, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245: 1066-1073. (Pubitemid 19231814)
9. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M and Rozmahel R, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245: 1059-1065. (Pubitemid 19231813)
10. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R and Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992, 2: 21-25.
11. High KA and Aubourg P. rAAV human trial experience. Methods Mol Biol 2011, 807: 429-457.
12. Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A and Herzog RW. Innate immune responses to AAV vectors. Front Microbiol 2011, 2: 194.
13. Wang Z, Tapscott SJ, Chamberlain JS and Storb R. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol 2011, 2: 201.
14. Kaufman HE. Adenovirus advances: new diagnostic and therapeutic options. Curr Opin Ophthalmol 2011, 22: 290-293.
15. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S and Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996, 93: 5731-5736.
16. Griesenbach U and Alton EW. Current status and future directions of gene and cell therapy for cystic fibrosis. BioDrugs 2011, 25: 77-88.
17. Kinloch R, Mackay N and Mautner V. Adenovirus hexon. Sequence comparison of subgroup C serotypes 2 and 5. J Biol Chem 1984, 259: 6431-6436. (Pubitemid 14108192)
18. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007, 36: 71-80. (Pubitemid 350133603)
19. Cao H, Koehler DR and Hu J. Adenoviral vectors for gene replacement therapy. Viral Immunol 2004, 17: 327-333. (Pubitemid 39244755)
20. Hemmi S, Geertsen R, Mezzacasa A, Peter I and Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998, 9: 2363-2373. (Pubitemid 28523985)
21. Kay MA, Glorioso JC and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001, 7: 33-40. (Pubitemid 32095639)
22. Graham FL, Smiley J, Russell WC and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36: 59-74.
23. Zaiss AK, Machado HB and Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009, 108: 778-790.
24. Nayak S and Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010, 17: 295-304.
25. Rasmussen UB, Benchaibi M, Meyer V, Schlesinger Y and Schughart K. Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum Gene Ther 1999, 10: 2587-2599.
26. Vetrini F and Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2010, 2: 1886-1917.
27. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP and Wilson JM, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80: 148-158. (Pubitemid 37272241)
28. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009, 96: 151-157.
29. Atchison RW, Casto BC and Hammon WM. Electron microscopy of adenovirus-associated virus (AAV) in cell cultures. Virology 1966, 29: 353-357.
30. Grieger JC and Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005, 79: 9933-9944. (Pubitemid 41022335)
31. Leigh MW, Kylander JE, Yankaskas JR and Boucher RC. Cell proliferation in bronchial epithelium and submucosal glands of cystic fibrosis patients. Am J Respir Cell Mol Biol 1995, 12: 605-612.
32. Mccarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008, 16: 1648-1656.
33. Koeberl DD, Pinto C, Sun B, Li S, Kozink DM, Benjamin DK, Jr. and Demaster AK, et al. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 2008, 16: 665-672. (Pubitemid 351426167)
34. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N and Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991, 10: 3941-3950. (Pubitemid 21905423)
35. Deyle DR and Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Ther 2009, 11: 442-447.
36. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW and Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317: 477. (Pubitemid 47196106)
37. Miller DG, Petek LM and Russell DW. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 2004, 36: 767-773. (Pubitemid 38886641)
38. Bell P, Wang L, Lebherz C, Flieder DB, Bove MS, Wu D and Gao GP, et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 2005, 12: 299-306. (Pubitemid 41025100)
39. Bell P, Moscioni AD, Mccarter RJ, Wu D, Gao G, Hoang A and Sanmiguel JC, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 2006, 14: 34-44. (Pubitemid 43922140)
40. Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE and Shah R, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 2011, 117: 3311-3319.
41. Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA and Arruda VR, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009, 50: 144-167.
42. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J and Van Ginkel FW, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009, 113: 797-806.
43. Frank KM, Hogarth DK, Miller JL, Mandal S, Mease PJ, Samulski RJ and Weisgerber GA, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med 2009, 361: 161-169.
44. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J and Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002, 99: 11854-11859. (Pubitemid 34994488)
45. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ and Calcedo R, et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003, 100: 6081-6086. (Pubitemid 36576934)
46. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X and Wilson JM. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004, 78: 6381-6388. (Pubitemid 38715936)
47. Mori S, Wang L, Takeuchi T and Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004, 330: 375-383. (Pubitemid 39572844)
48. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D and Chiorini JA. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 2008, 82: 1399-1406.
49. Kassim SH, Li H, Vandenberghe LH, Hinderer C, Bell P, Marchadier D and Wilson A, et al. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 2010, 5: e13424.
50. Jacobs F and Wang L. Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application. Curr Pharm Des 2011, 17: 2500-2515.
51. Allay JA, Sleep S, Long S, Tillman DM, Clark R, Carney G and Fagone P, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 2011, 22: 595-604.
52. Nathwani AC, Rosales C, Mcintosh J, Rastegarlari G, Nathwani D, Raj D and Nawathe S, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 2011, 19: 876-885.
53. Cunningham SC, Kok CY, Dane AP, Carpenter K, Kizana E, Kuchel PW and Alexander IE. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol Ther 2011, 19: 854-859.
54. Wang L, Bell P, Lin J, Calcedo R, Tarantal AF and Wilson JM. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol Ther 2011, 19: 2012-2020.
55. Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL and Wilson JM. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011, 22: 1389-1401.
56. ash mice using optimized self-complementary AAV2/8 vectors. Gene Ther 2012, 19: 404-410.
57. Qiao C, Li J, Zheng H, Bogan J, Yuan Z, Zhang C and Bogan D, et al. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 2009, 20: 1-10.
58. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K and Viswanathan A, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358: 2231-2239. (Pubitemid 351724452)
59. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L and Conlon TJ, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19: 979-990.
60. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr, Mingozzi F, Bennicelli J and Banfi S, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358: 2240-2248. (Pubitemid 351724453)
61. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F and Mingozzi F, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374: 1597-1605.
62. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA and Bland RJ, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369: 2097-2105. (Pubitemid 46935946)
63. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS and Aminoff MJ. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70: 1980-1983.
64. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA and Vanbrocklin HF, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73: 1662-1669.
65. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR and Tai SJ, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101: 2963-2972. (Pubitemid 36857981)
66. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ and Ozelo MC, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006, 12: 342-347. (Pubitemid 43355084)
67. Nathwani AC, Tuddenhman EG, Rangarajan S, Rosales C, McIntosh J, Linch DC and Chowdary P. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011, 365: 2357-2365.
68. Burns JC, Friedmann T, Driever W, Burrascano M and Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993, 90: 8033-8037. (Pubitemid 23260849)
69. Yee JK, Miyanohara A, Laporte P, Bouic K, Burns JC and Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994, 91: 9564-9568. (Pubitemid 24297955)
70. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H and Brugman MH, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118: 3143-3150.
71. Cavazzana-Calvo M, Hacein-Bey S, De Saint Basile G, Gross F, Yvon E, Nusbaum P and Selz F, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288: 669-672. (Pubitemid 30241569)
72. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J and Brouns G, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364: 2181-2187. (Pubitemid 40018447)
73. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, Mcintyre E and Radford I, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348: 255-256. (Pubitemid 36077924)
74. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Mccormack MP, Wulffraat N, Leboulch P and Lim A, et al., LMO2-associated clonal T-cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302: 415-419. (Pubitemid 37296260)
75. Naldini L, Blomer U, Gage FH, Trono D and Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93: 11382-11388. (Pubitemid 26347130)
76. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH and Verma IM, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272: 263-267. (Pubitemid 26119138)
77. Poeschla EM, Wong-Staal F and Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998, 4: 354-357. (Pubitemid 28144098)
78. Sinn PL, Burnight ER, Hickey MA, Blissard GW and Mccray PB, Jr. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 2005, 79: 12818-12827. (Pubitemid 41433201)
79. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998, 5: 1481-1487. (Pubitemid 28517375)
80. Limberis M, Anson DS, Fuller M and Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002, 13: 1961-1970. (Pubitemid 35341037)
81. Limberis MP, Bell CL, Heath J and Wilson JM. Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung. Mol Ther 2010, 18: 143-150.
82. Mitomo K, Griesenbach U, Inoue M, Somerton L, Meng C, Akiba E and Tabata T, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 2010, 18: 1173-1182.
83. Kobinger GP, Weiner DJ, Yu QC and Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001, 19: 225-230. (Pubitemid 32220562)
84. Medina MF, Kobinger GP, Rux J, Gasmi M, Looney DJ, Bates P and Wilson JM. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther 2003, 8: 777-789. (Pubitemid 37527453)
85. Kobinger GP, Limberis MP, Somanathan S, Schumer G, Bell P and Wilson JM. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum Gene Ther 2007, 18: 413-422. (Pubitemid 46850133)
86. Mckay T, Patel M, Pickles RJ, Johnson LG and Olsen JC. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther 2006, 13: 715-724.
87. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I and Vidaud M, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326: 818-823.
88. Bemelmans AP, Kostic C, Crippa SV, Hauswirth WW, Lem J, Munier FL and Seeliger MW, et al. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital am-aurosis. PLoS Med 2006, 3: e347.
89. Bemelmans AP, Kostic C, Cachafeiro M, Crippa SV, Wanner D, Tekaya M and Wenzel A, et al. Lentiviral gene transfer-mediated cone vision restoration in RPE65 knockout mice. Adv Exp Med Biol 2008, 613: 89-95.
90. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther 2008, 8: 419-429.
91. Mackenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S and Wilson JM, et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002, 6: 349-358. (Pubitemid 36305337)
92. Follenzi A, Sabatino G, Lombardo A, Boccaccio C and Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002, 13: 243-260. (Pubitemid 34164109)
93. Balaggan KS and Ali RR. Ocular gene delivery using lentiviral vectors. Gene Ther 2011, 19: 145-153.
94. Fuller M and Anson DS. Helper plasmids for production of HIV-1-derived vectors. Hum Gene Ther 2001, 12: 2081-2093. (Pubitemid 34053492)
95. Iwakuma T, Cui Y and Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999, 261: 120-132.
96. Porter DL, Levine BL, Kalos M, Bagg A and June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365: 725-733.
97. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M and Cesani M, et al. Lentiviral vector common integration sites in pre-clinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011, 117: 5332-5339.
98. Schmidt-Wolf GD and Schmidt-Wolf IGH. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med 2003, 9: 67-72. (Pubitemid 36313867)
99. Lee ER, Marshall J, Siegel CS, Jiang C, Yew NS, Nichols MR and Nietupski JB, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996, 7: 1701-1717. (Pubitemid 26340482)
100. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J and Davies J, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999, 353: 947-954. (Pubitemid 29132602)
101. Guo ZS and Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004, 4: 901-917. (Pubitemid 38843227)
102. Zhang L, Limberis MP, Thompson C, Antunes MB, Luongo C, Wilson JM and Collins PL, et al. Alpha-fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors. Hum Gene Ther 2010, 21: 1657-1664.
103. Zhang L, Collins PL, Lamb RA and Pickles RJ. Comparison of differing cytopathic effects in human airway epithelium of parainfluenza virus 5 (W3A), parainfluenza virus type 3, and respiratory syncytial virus. Virology 2011, 421: 67-77.
104. Zhang L, Peeples ME, Boucher RC, Collins PL and Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002, 76: 5654-5666. (Pubitemid 34517916)
105. Atkins GJ, Fleeton MN and Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008, 10: e33.
106. De Silva S and Bowers WJ. Targeting the central nervous system with herpes simplex virus/sleeping beauty hybrid amplicon vectors. Curr Gene Ther 2011, 11:332-340.
107. Murakami T and Sunada Y. Plasmid DNA gene therapy by electropor-ation: principles and recent advances. Curr Gene Ther 2011, 11: 447-456.
108. Xenariou S, Griesenbach U, Ferrari S, Dean P, Scheule RK, Cheng SH and Geddes DM, et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006, 13: 1545-1552. (Pubitemid 44567151)
109. Ni X, Castanares M, Mukherjee A and Lupold SE. Nucleic acid apta-mers: clinical applications and promising new horizons. Curr Med Chem 2011, 18: 4206-4214.
110. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, Mccleland ML and Bellinger D, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002, 99: 2670-2676. (Pubitemid 34525351)
111. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN and Tuddenham EG, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006, 107: 2653-2661.
112. Nathwani AC, Gray JT, Mcintosh J, Ng CY, Zhou J, Spence Y and Cochrane M, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007, 109: 1414-1421. (Pubitemid 46239572)
113. + T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007, 13: 419-422. (Pubitemid 46559826)
114. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT and Rouhani F, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009, 106: 16363-16368.
115. Zaiss AK and Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008, 15: 808-816. (Pubitemid 351712613)
116. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S and Bowles D, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010, 363: 1429-1437.
117. Limberis MP, Calcedo R, Griesenbach U, Alton EW and Wilson JM. Self-reactive T cells to CFTR in cystic fibrosis (CF) and non-CF humans: implications for gene therapy. Mol Ther 2011, 19: 43.
118. Brusilow SW and Horwich AL. Urea cycle enzymes. In: Scriver CR ed. The Metabolic Basis Olf Inhertited Disease. New York: McGraw-Hill, 1989: 629-663.
119. Batshaw ML, Msall M, Beaudet AL and Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 1986, 108: 236-241. (Pubitemid 16124812)
120. Maestri NE, Brusilow SW, Clissold DB and Bassett SS. Long-term treatment of girls with ornithine, transcarbamylase deficiency. New Engl J Med 1996, 335: 855-859. (Pubitemid 26304067)
121. Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P and Muenzer J, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab 2007, 91: 37-47. (Pubitemid 46550926)
122. Tarantal AF and Lee CC. Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta). Hum Gene Ther 2010, 21: 143-148.
123. Rahim AA, Wong AM, Howe SJ, Buckley SM, Acosta-Saltos AD, Elston KE and Ward NJ, et al. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther 2009, 16: 509-520.
124. Den Hollander AI, Roepman R, Koenekoop RK and Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008, 27: 391-419.